Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL814927 | 0.80 | CES2 (0.52) | ATMKMT2AHPGDTP53SMN1; SMN2 | |
| SCHEMBL451258 | 0.79 | ATM (0.54) | ALDH1A1TDP1RAB9AKDM4EATM | |
| SCHEMBL628981 | 0.78 | ATM (0.45) | ALDH1A1HDAC8HDAC6ATMKMT2A | |
| SCHEMBL815083 | 0.77 | PTGS2 (0.57) | ALDH1A1ATMCES2CES1 | |
| SCHEMBL9427231 | 0.76 | ALDH1A1 (0.56) | ALDH1A1KEAP1TDP1NPC1RAB9A | |
| SCHEMBL815888 | 0.75 | CES2 (0.56) | CES2CES1 | |
| SCHEMBL155800 | 0.75 | TDP1 (0.55) | TDP1NPC1RAB9ACASP3SENP8 | |
| SCHEMBL1305408 | 0.74 | ALDH1A1 (0.59) | ALDH1A1KEAP1TDP1NPC1RAB9A | |
| SCHEMBL4222999 | 0.74 | ALDH1A1 (0.59) | ALDH1A1KEAP1TDP1FFAR1GRIN1 | |
| SCHEMBL814748 | 0.73 | CES2 (0.58) | TDP1KMT2ACES2CES1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3389720-A1 | POLYACETAL POLYMERS, CONJUGATES, PARTICLES AND USES THEREOF | The General Hospital Corporation (US) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017106630-A1 | POLYACETAL POLYMERS, CONJUGATES, PARTICLES AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2017-06-22 | — | — | WO | disclosed |
| EP-2978785-A1 | PMMA PROVIDED WITH IMPACT RESISTANCE AND HAVING IMPROVED OPTICAL PROPERTIES | Evonik Röhm GmbH (DE) | 2016-02-03 | — | — | EP | disclosed |
| WO-2014154543-A1 | PMMA PROVIDED WITH IMPACT RESISTANCE AND HAVING IMPROVED OPTICAL PROPERTIES | EVONIK RÖHM GMBH (DE) | 2014-10-02 | — | — | WO | disclosed |
| US-20140141230-A1 | PERMANENT ATTACHMENT OF AMMONIUM AND GUANIDINE-BASED ANTIMICROBIALS TO SURFACES CONTAINING C-H FUNCTIONALITY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2014-05-22 | — | — | US | disclosed |
| US-20140134906-A1 | PERMANENT ATTACHMENT OF PIGMENTS AND DYES TO SURFACES CONTAINING CALKYL-OH FUNCTIONALITY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2014-05-15 | — | — | US | disclosed |
| US-20140134107-A1 | COMPOUNDS, PROBES, AND METHODS OF SYNTHESIS AND METHODS OF IMAGING COX-2-ASSOCIATED DISEASES | VANDERBILT UNIVERSITY | 2014-05-15 | — | — | US | disclosed |
| US-20140121333-A1 | PERMANENT ATTACHMENT OF AGENTS TO SURFACES CONTAINING C-H FUNCTIONALITY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2014-05-01 | — | — | US | disclosed |
| EP-1694357-A1 | USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC | AXYS PHARMACEUTICALS, INC. (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005058348-A1 | USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| EP-1261611-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001077102-A1 | MACROCYCLIC CHELANTS FOR METALLOPHARMACEUTICALS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-10-18 | — | — | WO | disclosed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | disclosed |
| US-5508273-A | ARALKYLPHOSPHONATES FOR OSTEOPOROSIS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-04-16 | — | — | US | disclosed |
| US-5300646-A | Intermediates for acylcoenzyme A:cholesterol acyltransferase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140141230-A1 | PERMANENT ATTACHMENT OF AMMONIUM AND GUANIDINE-BASED ANTIMICROBIALS TO SURFACES CONTAINING C-H FUNCTIONALITY | GMPS, ARG1, ALKBH1 | ALDH1A1 1320/4885KEAP1 3465/4885TDP1 1568/4885 |
| US-20140134107-A1 | COMPOUNDS, PROBES, AND METHODS OF SYNTHESIS AND METHODS OF IMAGING COX-2-ASSOCIATED DISEASES | PTGS2, PTGES2, PTGES | ALDH1A1 1170/4885KEAP1 594/4885TDP1 2221/4885 |
| US-20140134906-A1 | PERMANENT ATTACHMENT OF PIGMENTS AND DYES TO SURFACES CONTAINING CALKYL-OH FUNCTIONALITY | TYR, ALDH1A2, CALD1 | ALDH1A1 115/4885KEAP1 540/4885TDP1 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.